CAR-T Cell Therapy Highly Effective in Acute Lymphoblastic Leukemia

CTL019, a CAR T-cell therapy, had a high response rate for young patients with relapsed/refractory ALL in a recent phase 2 study.
BY SILAS INMAN @silasinman
According to findings from the global phase 2 ELIANA study, CTL019, a CAR T-cell therapy, had an 82 percent complete remission (CR) or CR with incomplete blood count recovery (Cri) rate for pediatric and young adult patients who had relapsed/refractory B-cell acute lymphoblastic leukemia (ALL).

The phase 2 study enrolled patients at 25 centers in the United States, Europe, Asia and Australia. In the first 50 patients enrolled, the CR rate was 68 percent and the CRi rate was 14 percent. All patients with a CR/CRi also tested negative for minimal residual disease. The six-month overall survival rate was 89 percent and the disease-free survival rate was 60 percent.

"There was high efficacy, with the primary endpoint met. All complete remissions were MRD-negative and durable," said lead investigator Stephan Grupp, M.D., Ph.D., the Yetta Deitch Novotny Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. "These global multicenter trial data build on earlier encouraging research conducted at a single trial site, and advance the case for CTL019 as a potential treatment for children and young adults with relapsed or refractory B-cell ALL.”

Novartis, the company developing the CAR T-cell therapy, plans to submit regulatory applications to the FDA and European Medicines Agency (EMA) for CTL019 as a treatment for pediatric and young adult patients with relapsed/refractory B-cell ALL, based on findings from ELIANA. The company expects to complete the submissions in early 2017.

"We are committed to advancing CTL019 and look forward to working closely with the FDA and EMA in the coming months," Bruno Strigini, CEO, Novartis Oncology, said in a statement. "This first-of-its-kind trial represents exciting progress toward our goal of helping children and young adults with relapsed or refractory B-cell ALL, a patient population with an urgent need for new treatment options."

The ELIANA study enrolled 81 patients, of which five are awaiting infusion and 14 discontinued prior to infusion due to deaths (five patients), manufacturing failures (five patients) and adverse events (three patients). The primary efficacy analysis was conducted after a median of 4.3 months of follow-up for the first 50 patients treated with CTL019.

All patients received lymphodepleting chemotherapy prior to infusion of CTL019. Fludarabine was administered at 30 mg/m2 daily for four doses and cyclophosphamide was given at 500 mg/m2 daily for two doses.

CTL019 was manufactured in the United States at a Novartis facility for all patients, even those in Europe and Asia Pacific. In some instances, 41 days elapsed from the time of enrollment to infusion. "This was a global trial, with most eligible patients able to receive CTL019 in a timely manner utilizing central manufacturing," Grupp noted.

Talk about this article with other patients, caregivers, and advocates in the Leukemia CURE discussion group.
Special Feature
Share Your Art
Related Articles
Examining the Safety of CLL Medication
OVER THE LAST FEW years, significant advances were made in the treatment of patients with chronic lymphocytic leukemia (CLL). Several novel therapies, most of them oral, have now been approved by the Food and Drug Administration. These include Imbruvica (ibrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor; Venclexta (venetoclax), a B-cell lymphoma-2 (BCL2) inhibitor; and Zydelig (idelalisib), a phosphoinositide 3-kinase (PI3K) inhibitor.
Drug Provides High Response Rate in CLL
Venclexta (venetoclax), a BCL-2 inhibitor, had promising results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). According to an updated analysis of a clinical trial, the agent led to negative minimal residual disease (MRD) in 40 percent of patients involved.  
Treatment Stages for a Rare Leukemia
THERE ARE THREE STAGES of treatment for acute promyelocytic leukemia: induction therapy, consolidation therapy and maintenance therapy.
Related Videos
Dr. Stuart Goldberg Answers Common Questions From CML Patients
Stuart Goldberg, hematologist/oncologist at John Theurer Cancer Center, discusses some of the common questions he gets from his patients with chronic myeloid leukemia.
//For side ad protocol